EMEA-002468-PIP04-18

Key facts

Active substance
belantamab mafodotin
Therapeutic area
Oncology
Decision number
P/0347/2019
PIP number
EMEA-002468-PIP04-18
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Multiple Myeloma
Route(s) of administration
Intravenous use
Contact for public enquiries
GlaxoSmithKline Trading Services Limited

Tel. +44 (0)20 8990 3836
E-mail: eu.paediatric-plans@gsk.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating